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Introduction
Research has focused on identification of selection criteria 
for surgery in a multimodality therapy approach since 1976, 
when Butchart in Newcastle, UK described the importance 
of precise patient selection for surgery. He was one of the 
pioneers in mesothelioma surgery and concluded, after a 
series of 29 patients undergoing pleuropneumonectomy, that 
death could have been prevented by better case selection, 
alteration in surgical technique, and better postoperative 
management (1). To optimize patient selection, many factors 
have to be taken into account: the patients’ performance 
status (PS), the stage of disease, and also availability and 
access to different treatment approaches. In the following 
chapter, clinical and pathological staging and prognostic 
factors will be summarized.
Clinical prognostic factors—fitness for surgery
In general, prognostic factors can be classified into clinical 
(including hematological/serum) and pathological/
molecular features. Butchart divided his cohort in 1976 
into “fit” and “unfit for surgery” and categorized them 
additionally in “above 60 years” or “below 60 years of 
age” (1). The selection process to decide which patient is 
eligible for surgery is challenging and requires expertise 
and interdisciplinary collaboration. The following known 
risk factors additionally associated with poor prognosis 
on overall survival (OS) have been identified for patients 
undergoing surgery for malignant pleural mesothelioma 
(MPM): age, patient’s comorbidities, weight loss, PS, 
anemia, high platelet count (PLT), male gender and non-
epithelioid subtype (2-7). In one of the first studies by 
Curran and colleagues, poor PS (Eastern Cooperative 
Oncology Group PS: ECOG 1 or 2), high white blood cell 
(WBC) count (>8.3×109/L), probable or possible histologic 
diagnosis of sarcomatoid subtype, and male gender were in 
general associated with poor prognosis (4,8,9). Additionally, 
in a study by van Meerbeeck et al., low level of hemoglobin 
was a negative prognostic factor for patients undergoing 
palliative chemotherapy at a hemoglobin difference of ≥1 
from the baseline values of 16 g/dL in men and 14 g/dL in 
women (8).
In general, age is currently a less stringent exclusion 
Review Article
Patient selection for radical surgery for mesothelioma—prognostic 
factors in a multimodality approach
Olivia Lauk, Isabelle Opitz
Department of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland
Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: I Opitz; (IV) 
Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of 
manuscript: All authors.
Correspondence to: Isabelle Opitz, MD, FEBTS. Department of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, 
Switzerland. Email: isabelle.schmitt-opitz@usz.ch.
Abstract: In the absence of standardized treatment algorithms for malignant pleural mesothelioma patients, 
one of the main difficulties remains patient allocation to therapies with potential benefit. In the following 
article, we discuss clinical, pathological and molecular prognostic factors, which have been investigated over 
the past years to simplify and at the same time specify patient selection for multimodality treatment. 
Keywords: Patient selection; malignant pleural mesothelioma-prognostic factors; multimodality treatment; 
surgery
Received: 31 January 2018; Accepted: 06 August 2018; Published: 29 September 2018.
doi: 10.21037/shc.2018.09.01
View this article at: http://dx.doi.org/10.21037/shc.2018.09.01
Shanghai Chest, 2018Page 2 of 13
© Shanghai Chest. All rights reserved. Shanghai Chest 2018;2:73shc.amegroups.com
criterion for surgery with changing demographics. Age 
in isolation is not necessarily associated with increased 
morbidity or mortality as investigated by Williams and 
colleagues in patients who underwent extended pleurectomy 
and decortication (EPD) (10). Fitness for surgery needs 
to be assessed by pulmonary function testing and cardiac 
assessment (11). There are no clear contraindications for 
mesothelioma surgery in terms of certain comorbidity 
profiles. However, the American College of Cardiology and 
the American Heart Association (ACC/AHA) guidelines 
established a “Revised Cardiac Risk Index” (RCRI) for 
a better preoperative risk stratification of patients who 
need further cardiac evaluations compared to those 
who are eligible for surgery after basic routine cardiac 
assessments (12). This RCRI was evaluated in “a patient 
group undergoing non-cardiac surgery who is at risk for 
perioperative cardiac morbidity or mortality” based on 
general recommendations and a review of more than 400 
articles. It consists of 6 factors: chronic renal insufficiency, 
insulin-dependent diabetes mellitus, cerebrovascular disease, 
heart failure, ischemic heart disease, and high-risk surgical 
procedure. The common approach for general cardiac 
stratification starts with basic physical examination and 
baseline electrocardiography (ECG). ECGs preoperatively 
are required if the patient would need cardiac assessment 
even if there is no surgery planned or in case of clinical 
symptoms or signs of valve/left ventricular dysfunctions, 
as well as patients with established or documented 
coronary diseases. Especially, in assessment for extrapleural 
pneumonectomy (EPP), pulmonary hypertension needs 
to be excluded, at least by transthoracic echocardiography. 
If the RCRI is equal or above 2 points or the patient is 
not able to climb 2 flights of stairs, is on special cardiac 
medication, or has a newly diagnosed or suspicion of cardiac 
dysfunction, further assessment according to the AHA/ACC 
guidelines are necessary. Further tests such as non-invasive 
stress testing or echocardiography are required for patients 
at risk. 
In conclusion, all of the published “cardiac assessment” 
scores are intended to give a better risk stratification and 
should be used as a screening tool and not as a decision-
maker. The limitation of these scores is that they were 
investigated in different patient groups; mostly in patients 
undergoing lung resection without the differentiation of 
cancer or non-cancer derived illness. These algorithms 
should be used with care and should only give the risk 
profile of the patient. Overall, the decision to undergo 
surgery or not should still be made individually. 
A careful case history and a symptom orientated clinical 
examination cannot be replaced by any score.
Pre-operative assessments of pulmonary function are 
equally mandatory for both procedures, EPP or EPD. To 
our knowledge, there is no mesothelioma specific patient 
selection concerning the preoperative lung function 
and only a few reports concerning pulmonary function 
after EPP or pleurectomy/decortication (P/D) or EPD 
are reported in literature (13-16). The selection criteria 
for pneumonectomy for lung cancer can be applied for 
EPP assessment according to ERS/ESTS guidelines. 
Even if lung sparing procedure is the initially planned 
approach, pneumonectomy may become necessary during 
the operation and therefore feasibility has to be assessed 
preoperatively. The forced expiratory volume in 1 second 
(FEV1) for nearly all patients must be greater than 2 L to 
be able to perform the surgery up to pneumonectomy (16). 
In addition, quantitative ventilation/perfusion scanning and 
predicted postoperative (PPO) FEV1 (ideally more than 
1.2 L) are necessary to assess for an optimal preoperative 
diagnostic work up. FEV1 and carbon monoxide lung 
diffusion capacity (DLCO) should be above 80% for a 
resection up to pneumonectomy to be feasible (15). Markos 
and colleagues showed in 1989, that a PPO DLCO of 
40% was the best predictor of postoperative respiratory 
failure, morbidity, and mortality in patients with pulmonary 
resection up to pneumonectomy (17).
Furthermore, V/Q scan helps to estimate more precisely 
the PPO FEV1, as in many cases perfusion of the diseased 
side is dramatically reduced and therefore patients are 
already before operation “functionally pneumonectomized” 
(16,18-20). On the other hand, trapped lungs and pleural 
effusion may influence the lung function assessed in a “false 
negative way” and can definitely even improve after P/D. 
The preoperative evaluation of patients with entrapped lung 
by either pleural effusion or tumor remains challenging, 
pulmonary lung function tests are not conclusive and have 
to be interpreted with caution.
Another important factor is the patients’ individual 
expectancy to postoperative quality of “active” life. For 
some patients, special hobbies like hiking or playing musical 
instruments necessitate sufficient lung volume, which is 
asking for adaptation to the “normal” thresholds of PPO 
FEV1. This goes in line with the quality of life (QoL) to 
be expected for every patient after surgery, which needs to 
be discussed equally on an individual base. Looking at the 
available literature for QoL after surgery, data are scarce 
and very heterogeneous (13). 
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As of today, there are only two observational studies 
directly comparing QoL after EPP and P/D (14,21). 
There are many other studies investigating QoL after EPP 
or P/D without directly comparing the two procedures 
among each other (13,22,23). Some of these studies 
demonstrate a tendency for better QoL after lung sparing 
surgery compared to EPP. These two observational 
studies concluded that patients undergoing EPP had a 
greater deterioration in lung function postoperatively and 
consequently in QoL compared to patients undergoing 
EPD up to 12 months after surgery. This might be related 
to the fact that with decortication of entrapped lungs, lung 
function and therefore QoL can improve.
Pathological and molecular prognostic factors
The first TNM staging system for mesothelioma was 
proposed by the International Mesothelioma Interest 
Group (IMIG) in 1994 (24). Since then, this staging system 
has been revised several times (2,25,26). The IASLC 
Mesothelioma Staging Project utilized data from 29 centers 
worldwide, each providing post-operative data, in order 
to develop the 8th edition of the TNM classification. This 
revised TNM staging system affects the patient selection 
in order to increase the number of lower stages suitable for 
surgery without compromising OS, because in multivariate 
analyses, there was no significant survival benefit between 
stage I and II (25). Overall, patients with former advanced 
diseases according to the old TNM-classification, not 
feasible undergoing surgery, are downstaged through 
this new TNM-classification resulting in an increased 
resectability of MPM. There are no precise selection 
criteria based on T-factors alone, as clinical staging is too 
imprecise (27-29). For a better evaluation of resectability 
in terms of tumor load, tumor volume is an attractive 
parameter. As described first in 1998 by Pass and colleagues, 
and later also by us, preoperatively assessed tumor volume 
is representative of T-status in MPM (30) and can predict 
overall and progression-free survival, as well as postoperative 
stage (27). In that same study they showed that large volumes 
are associated with nodal spread as well as post resection 
residual tumor burden and may predict outcome (Figure 1) 
(27,30-32). In another study, Gill et al. showed an association 
of tumor volume and OS (independently), especially if 
the tumor volume was greater than 500 cm3. This means, 
patients with a tumor volume greater than 500 cm3 
showed a poorer OS (33).
Further evaluation in a multicenter network by Rusch 
and colleagues, showed a correlation between tumor 
volume and pT/pN stages plus OS. Within this analysis 
they defined three groups with tumor volumes of 91.2, 
245.3, and 511.3 cm3 and showed that these tumor volumes 
were associated with a median OS of 37, 18, and 8 months, 
respectively (32). 
In the last proposals for revision of the T Descriptors, 
it was demonstrated that survival correlated with pleural 
thickness. Pleural thickness showed an increase at higher 
T-stages and it was significantly associated with node 
positivity and overall stage. Based on these findings, data 
from the seventh edition of T-categories and overall stage, 
survival showed a median survival of 23.4 months for the 
lowest tumor thickness (<16.0 mm) compared to a median 
survival of 13.2 months for the highest tumor thickness 
(>50.0 mm) (26). Nevertheless, further investigations as 
to whether tumor thickness should be included in future 
staging systems are necessary.
Another prognosticator is the status of mediastinal lymph 
node involvement (N-factor). The current and former 
editions of N-descriptor of the TNM-classification are 
based on the lung cancer staging system and are therefore 
not MPM-specific. The general applicability of lymph node 
involvement in MPM patients is not clear, as the lymphatic 
drainage in the two cancers is different. Mesothelioma 
is primarily a parietal pleura disease, N2 rather than N1 
nodes may potentially be the first draining nodal station 
for this tumor, so hilar or peribronchial node involvement 
may carry a less favorable prognosis than paratracheal or 
subcarinal nodes (34). Former N2 is now N1 and N3 is now 
N2 with the rationale that affected subcarinal, ipsilateral 
Figure 1 Influence of preoperative size on overall survival of 
patients having cytoreduction for malignant pleural mesothelioma 
(1998, Pass) (30).
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mediastinal lymph nodes as well as lymph nodes from the 
mammary drainage area do not have a significant effect 
on OS. Intrapleural and extrapleural lymph node stations 
are incorporated with the conclusion, that N1 lymph 
nodes become secondarily involved only when invasion of 
lung parenchyma occurs (35). Besides IASLC data, poor 
reliability of N-descriptor on survival was demonstrated in 
several studies. In a study by Hysi et al. nodal involvement 
regardless of N1 or N2, significantly reduced the median 
survival as it was 12.7 months for N+ (N1–N2) staged 
patients compared to 22.4 months for N0 staged patients. 
The number of involved or total removed lymph nodes 
was not related to OS (36). On the contrary, in a study by 
Edwards et al., the number of positive nodes correlated 
with survival. The number of involved stations and their 
anatomic location however did not. Nevertheless, this 
study also showed that N2 metastases were associated with 
reduced survival, but as in the study by Hysi et al. there was 
no difference between N1 and N2 cases (37). In conclusion, 
this means that nodal involvement seems to be of prognostic 
importance but the location in the mediastinum has to be 
interpreted differently from lung cancer. Therefore, the 
N-descriptor was revised for the eighth TNM-classification 
to more MPM-specific N-categories in comparison to the 
seventh edition system, where the median survival for cN0 
patients was 19 months versus 17.6 and 16.2 months for 
cN1 and cN2 patients, respectively and without statistical 
significance (35).
Distant metastases (M1) can be detected by 18F-fluoro-
2-deoxy-D-glucose positron-emission tomography (FDG-
PET) scans with an accuracy of 90.3% according to a 
study by Yildirim et al. (38,39). In the proposal for the 
eighth edition for TNM-classification in MPM patients, 
distant metastases were divided into two categories: single 
metastasis or single site of metastatic disease compared to 
multiple lesions or sites. After revision of the MPM TNM-
classification, the categorization of distant metastases 
appears to be associated with a different OS (40). Obviously, 
these patients should not be included into surgery protocols. 
Concluding, an improved staging system will also 
contribute to an improved conformity between different 
medical centers in respect to a more precise comparison of 
patient’s selection and outcome (41).  
The prognostic impact of many pathological or 
molecular markers is not fully clarified yet. The main goal 
is an early detection, which leads to early diagnosis, hence 
early treatment. The histological subtypes, for example, 
help to identify patients eligible for surgery or not. The 
newest ASCO guidelines 2018 by Kindler and colleagues 
confirm the known better OS (19 months) for patients with 
epithelioid subtype undergoing surgery compared to patients 
with biphasic or sarcomatoid subtype with an OS of 12 and 
4 months, respectively (42,43). Biphasic or sarcomatoid 
subtype with negative mediastinal lymph node status, 
however, should not be excluded from surgery, because this 
can be the only option for these patients in terms of their 
higher incidence of chemoresistance (44-46). In conclusion, 
the decision for or against surgery should not be based on a 
single factor as histotype, but rather respect a combination 
of various factors, as there are certain cases of biphasic or 
sarcomatoid histotypes with long term survival (47,48). 
In the following, we will discuss briefly a few molecular 
prognosticators being a focus of our research area, but not 
in depth as this is the topic of following chapters.
PD-L1 as a novel target for molecular findings with a 
high interdisciplinary popularity nowadays, may predict the 
behavior of MPM, and is possibly associated with a lower 
median survival according to a newly released study by 
Nguyen et al. (49). In this study, a positivity of PD-L1 was 
associated with a median survival of 6 months compared 
to survival associated with negative PD-L1 expression of 
15.5 months. 
There are two recently published reviews by Chen et al. 
and Sun et al., groups from the University of Hawaii Cancer 
Center and NYU Langone Medical Center (50,51). The 
authors listed the most promising markers associated with 
diagnosis and prognosis of MPM in the current research 
field. Those are, soluble mesothelin-related proteins 
(SMRPs), osteopontin, Fibulin-3, high-mobility group 
box 1 (HMGB 1), micro-RNA (miRNA), proteomics, and 
peripheral blood-based markers [lymphocyte-to-monocyte 
ratio (LMR), neutrophil-to-lymphocyte ratio (NLR) and 
platelet-to-lymphocyte ratio (PLR)]. These markers—
so far—do not have an impact in patient selection suitable 
for multimodality therapy approaches. All of them will be 
briefly discussed below. 
SMRP is the most studied and the only Food and Drug 
Administration (FDA)-approved biomarker, which can be 
additionally used for monitoring (52). It consists of two 
major proteins. One part of it is released into the blood and 
the other part is a plasma membrane-bound protein (53-56). 
The prognostic value is still controversially discussed and is 
not yet finally clarified.
Osteopontin is a circulating glycoprotein in the serum 
and more established as a diagnostic biomarker than having 
a prognostic impact (57). Pass et al. showed that high 
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osteopontin levels were associated with poorer prognosis 
after adjusting these markers to the European Organisation 
for Research and Treatment of Cancer (EORTC) 
prognostic index (PI). This was proven in a final prognostic 
model (58).
Fibulin-3, also a glycoprotein and encoded by epidermal 
growth factor (EGF)-containing fibulin-like extracellular 
matrix protein-1 (EFEMP-1) gene, is a valuable biomarker 
for MPM diagnostics, but has not yet been investigated 
in a prospective manner (59,60). Kirschner et al. (59) 
demonstrated in two independent cohorts that low levels 
of fibulin in pleural effusion were associated with better 
survival (hazard ratio of 9.92). 
HMGB 1 is a damage associated molecular pattern 
(DAMP) protein and released by necrotic cells. Besides 
its role as a diagnostic marker, it also has prognostic value 
(61,62), with an inverse association between HMGB 1 
serum levels and survival at a cut off value of 9 ng/mL.
MicroRNAs are small non-coding RNA molecules, 
which regulate gene expression (63,64). So far, 2,588 
human miRNAs have been identified. Kirschner et al. (65) 
established a miR-Score consisting of 6 miRNAs (miR-21-
5p, miR-23-3p, miR-30e-5p, miR-221-3p, miR-222-3p) 
predicting longer survival in positive patients. 
Proteomics represents a technique to screen serological 
markers of the proteome. Proteome is the entire set of 
proteins expressed by an organism at a certain time. They 
are only marginally investigated so far and therefore not 
further discussed in this paper. 
A recently published meta-analysis of the prognostic 
significance of NLR ratio in patients treated surgically 
and non-surgically also concluded that NLR might have a 
prognostic role as biomarker in MPM (66).
Lastly, the most promising hematological marker is 
the peripheral blood-based marker LMR given its proven 
correlation with survival. Yamagishi and colleagues showed 
that patients with a LMR serum level greater than 2.74 
had an improved OS of 14 months versus 5 months (67) 
for patients with a lower serum level. For the other blood 
markers like NLR and PLR, further studies are needed to 
show their influence as prognostic markers.
Other molecular prognosticators have to be mentioned 
and will be discussed below, such as chromosome alterations 
of CDKN2A locus (9p21.3), homozygous p16 deletions 
(especially for sarcomatous type), and BAP1 mutations. All 
of them are associated with poor prognosis (68-70). 
BRCA1-associated protein-1 (BAP1), a tumor suppressor, 
is highly discussed lately as a potential prognosticator for 
MPM, but the prognostic value of somatic BAP1 mutations 
remains to be evaluated. 
Another large study demonstrated that BAP1, NF2, 
and CDKN2A, were the three most frequently altered 
genes. CDKN2A mutations occurred in 10 of 22 MPM 
samples and were the most common event (71) of all gene 
alterations.
Our group investigated the influence of phosphatase 
and tensin homologue (PTEN) and its pathways on OS of 
mesothelioma patients (72,73). The data showed, that high 
p-S6 and Ki-67 expression in treatment naïve patients was 
associated with shorter progression-free survival. This, as 
well as a shorter OS, also applies for high Ki-67 expression 
after chemotherapy. In addition, they observed that a 
decrease in PTEN and an increase in p-mTOR expression 
during induction chemotherapy were associated with 
shorter OS (73). Furthermore, Meerang et al. discovered 
that low Merlin expression and high Survivin expression are 
also associated with a poorer prognosis (74). They showed 
that Ki-67 and a high nuclear Survivin labeling index in 
pre- and post-chemotherapy tissues were associated with 
shorter freedom from recurrence (73,74).
In summary, while all of these markers showed promising 
results, most have yet to be independently and prospectively 
validated, and for some of them controversial results from 
different studies concerning their prognostic impact need to 
be addressed (51). So far, all these above-mentioned markers 
and their potential prognostic value have no impact in 
patient selection, but may be included in selection algorithms 
alongside with clinical markers in prognostic scores.
Prognostic scores
For cl inical  use,  several  groups tried to combine 
independent prognostic factors to create a score for 
easier and better risk stratification (69,75-77). The 
EORTC and the Cancer and Leukaemia Group B 
(CALGB) developed a prognostic score for a better 
identification of patients, receiving different chemotherapy 
regimens, by analyzing the patient’s pretreatment 
characteristics (4,5). Lactate dehydrogenase (LDH) 
>500 IU/L, poor PS, chest pain, PLT >400,000/µL, 
non-epithelial histology, and increasing age older than 
75 years jointly predict poor survival and are predictive of 
a greater risk of dying early. The median survival for PS 
2, 1, and 0 was 3.3, 7.6, and 10.9 months respectively, for 
presence of chest pain 5.4 compared to 8.8 months without 
chest pain, for PLT above the cut off limit 6.2 compared 
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to 9.4 months, for weight loss 5.1 months compared 
to 7.9 months for no weight loss, for LDH 3.4 months 
compared to 7.6 months with low LDH (5). This score was 
validated in a retrospective study in patients undergoing 
surgery followed by chemotherapy regimens and eventually 
radiotherapy or undergoing a palliative procedure followed 
by chemotherapy, by the Italian group of Ruffini and 
colleagues and proved to be an independent prognostic 
factor (75). Edwards and colleagues also validated the 
effectiveness of the EORTC and CALGB systems. The 
patient population was heterogeneous, some patients only 
had surgical biopsy, some underwent surgical resection 
and in 23 cases, it was not possible to determine the 
surgical procedure. They had similar survivals for patients 
stratified into low risk and high-risk groups and correlated 
with the EORTC series with a median survival of 9.4 vs. 
10.8 months (low-risk group) and 3.8 vs. 5.5 months (high-
risk group), respectively (3,6,30,78). Shortly after the 
EORTC and CALGB Score, Pass, Rusch and colleagues 
identified covariates that were prognostically important for 
prediction of survival. These variables were stage, age, sex, 
histology (epithelioid vs. non-epithelioid), and the type of 
surgical procedure (palliative vs. EPP or P/D) and defined 
as “CORE” values (79). Additionally to these CORE 
variables, which were independently statistically significant, 
they analyzed their impact on OS: adjuvant therapy (yes: OS 
18 months vs. no: OS 10 months), smoking history (no: OS 
16 months vs. yes: OS 15 months), history of asbestos 
exposure (no: OS 17 months vs. yes: OS 15 months), history 
of weight loss, defined as greater than 5% (OS 11 months) 
vs. less than 5% (OS 17 months) in the previous 6 months, 
ECOG PS 0 (OS 22 months) and 1 (OS 16 months), 
chest pain (no: OS 19 months vs. yes: OS 14 months), and 
dyspnea (no: OS 15 months vs. yes: OS 17 months) as well 
as laboratory parameters [hemoglobin level (<14.6 OS 
16 months vs. >14.6 OS 20 months), PLT (<400 OS 19 months 
vs. >400 OS 12 months), WBC count (<15.5 OS 16 
months vs. >15.5 OS 8 months), and LDH level before the 
attempted surgical procedures). In total, they defined three 
prognostic models with these covariates. Models 1 and 2 in 
common is the inclusion of the CORE variables. Model 1 
additionally included adjuvant treatment, WBC count, and 
platelets. Further in the analysis with stepwise regression 
all covariates with the least significance were excluded until 
only significant covariates remained and this led to models 
2 and 3. Model 2 consists of the same covariates as model 1, 
but without a surgical proofed staging. Therefore, instead 
of calling it the best pathological stage it was changed to 
the term clinical stage. Furthermore, hemoglobin was 
added as additional laboratory parameter. Model 3 shows 
only parameters available before surgery (histology, sex, 
age, WBC count, hemoglobin, and platelets) and therefore 
simulates the potential surgical patient. Unfortunately, 
the models per se were not analyzed as to their prognostic 
value, only their covariates were individually indicated with 
their prognostic significance and hazard ratio (79,80).
In 2012, we defined a new multimodality prognostic 
score, only using parameters being available before 
surgery to support decision making. The items in the 
score consisted of tumor volume before chemotherapy 
(>500 mL), non-epithelioid histological diagnosed before 
chemotherapy, CRP >30 mg/L before chemotherapy, and 
progressive disease (PD) after chemotherapy. The cutoff 
within this score was at 2. The median OS for patients with 
a score of 0, 1, and 2 was 34, 17 and 12 months respectively. 
Whereas patients with a score of 3 or 4 had a median OS 
of 4 months (Figure 2). This score was further validated in 
an independent cohort of patients from a center in Vienna 
Figure 2 MMP score. Kaplan-Meier curve comparing overall 
survival (OS) according to the multimodality prognostic score 
(MMP score) in patients treated with induction chemotherapy 
followed by macroscopic complete resection (MCR) (n=223): 
score 0 (n=28): median OS 46 months [95% confidence interval 
(CI): 0–97 months]; score 1 (n=57): median OS 23 months (95% 
CI: 13–33 months); score 2 (n=28): median OS 15 months (95% 
CI: 11–18 months); score 3 (n=4): median OS 6 months (95% CI: 
0–12 months); score 4 (n=1): median OS 4 months (95% CI: not 
available); P<0.001 (updated unpublished data from Opitz 2015).
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(Figure 3). The comparison of MMPS score with EORTC 
score using ROC analysis at 2 years showed that the MMPS 
demonstrated a better predictive power for OS than the 
EORTC score (81).
Allocation to P/D, EPD or EPP
There is a notable transition in surgery for MPM from 
EPP to EPD (82). Crucial for this shift was a rethinking 
after the MARS trial study. EPP was associated with 
mortality that was not seen with chemo alone, although 
the study was not designed to test the benefit of EPP 
(83,84). A follow up study “MARS 2: A Feasibility Study 
Comparing (Extended) Pleurectomy Decortication Versus 
no Pleurectomy Decortication in Patients With Malignant 
Pleural Mesothelioma (MARS2)” (NCT02040272) was 
satisfactorily completed and the phase III trial is underway 
in the United Kingdom. Other studies tried to demonstrate 
survival differences between EPP and extended EPD with 
a trend towards the less radical lung sparing procedure. 
The main drawback of EPP is the higher mortality rate 
compared to EPD (85). The OS also tends to be superior 
for patients undergoing EPD compared to EPP at least for 
early stages (82,86-88). 
After many years of tradition in performing EPP for 
MPM patients, our institution shifted towards EPD in 
more than 90% of the cases with similar survival outcomes 
(Figures 4,5) [(89) and updated unpublished data] and very 
low mortality rates after EPD (0%). Generally, mortality 
rates are certainly lower after EPD as described in a 
systematic review by Cao et al. of 2.9% compared to 6.8% 
after EPP. Morbidity rates are as high as after EPP, when 
prolonged air leaks are taken into account, if not, morbidity 
rates for EPD are lower with 27.9% compared to 62.0% 
undergoing EPP (88).   
To date, we always aim for a lung sparing procedure. 
However, there are still situations where EPP might be the 
better procedure or even the only possible procedure due to 
the given tumor load. The challenge is to identify these cases 
upfront surgery, and therefore, in most cases, the decision 
is taken only during the operation. In case of unambiguous, 
deep lung tissue infiltration at multiple locations, or central/
hilar tumor mass infiltrating hilar vessels, pneumonectomy 
will be performed. Preoperatively, these situations are hardly 
detectable by CT scan or PET/CT scan.
Based on restaging imaging by contrast enhanced 
Figure 3 Kaplan-Meier curve of overall survival (OS) in months of the multimodality prognostic score [including four variables: tumor 
volume pre-CTX >500 mL, C-reactive protein level (CRP) pre-CTX >30 mg/L, nonepithelioid histology in pre-CTX biopsy, and 
progressive disease according to modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria]: (A) patients treated with 
induction chemotherapy followed by extrapleural pneumonectomy (EPP; Zürich); (B) patients treated with induction chemotherapy 
followed by EPP (Vienna). CTX, chemotherapy; EPP, extrapleural pneumonectomy. 
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CT scan or PET/CT after induction chemotherapy and 
assessment of modified Response Evaluation Criteria in 
Solid Tumors (mRECIST) (90), patients are classified 
as PD, stable disease, or partial response and if they are 
potentially resectable or not. mRECIST is a method most 
widely used for measurements in solid tumors. It is based 
on “unidimensional measurements of tumor thickness 
perpendicular to the chest wall or mediastinum” (90,91). 
Because of the difficulties in reproducibility, we are 
additionally using the delta of pre- and post-chemotherapy 
volume assessed by a dedicated software (27) (Figure 6). 
PD alone is not an exclusion criteria per se for surgery as 
long as macroscopic complete resection is still feasible. In 
some cases, further radiological assessments with magnetic 
resonance imaging (MRI) and functional imaging with 
FDG-PET need to be conducted to rule out chest wall 
infiltration, transdiaphragmatic infiltration, or nodal 
involvement and occult metastasis (39,92). Time between 
last cycle of induction chemotherapy and surgery should 
not exceed 6 weeks post induction chemotherapy (93). 
Obviously,  al l  patients should be discussed in an 
interdisciplinary tumor board consisting of pulmonologists, 
radiologists, radio-oncologists, oncologists, pathologists, 
and thoracic surgeons experienced in mesothelioma 
resections. Tumor stages I–III and all histologies are 
Figure 4 Induction chemotherapy followed by extrapleural 
pneumonectomy (EPP) versus induction chemotherapy followed 
by (extended) pleurectomy/decortication (P/D). Kaplan-Meier 
curve comparing overall survival (OS) in patients treated with 
induction chemotherapy followed by EPP (n=150) [median OS 
22 months; 95% confidence interval (CI): 20–24 months] versus 
patients treated with induction chemotherapy followed by P/
D (n=73) (median OS 30 months; 95% CI: 26–34 months), log 
rank test P=0.005. Zürich unpublished data (1999–2017). CTX, 
chemotherapy.
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International Mesothelioma Interest Group (IMIG) pathological 
stage and histological subtype (2:1 ratio). (A) Significant difference 
in OS between patients treated with EPP (n=52) (median OS: 
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95% CI: 10–17 months). CI, confidence interval; EPP, extrapleural 
pneumonectomy; FFR, freedom from recurrence; OS, overall 
survival; P/D, pleurectomy/decortication; CTX, chemotherapy. 
Kostron, 2017 (89).
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Figure 6 Volumetry of malignant pleural mesothelioma. The tumor itself (A) and the marked tumor (B, white) on a single computed 
tomography slice (with courtesy of Prof. Frauenfelder). 
A B
included if deemed technically resectable, with most of the 
patients treated within clinical trial protocols. Decisions 
leading to surgery are made individually and even localized 
chest wall infiltration is accepted if chest wall resection seems 
feasible and reasonable at only one level. Furthermore, our 
MMPs score is used as exclusion criterion (MMPS ≤2). The 
procedure of choice is EPD if technically and oncologically 
feasible (82,86,87,94). Only in cases of multiple spots with 
direct lung parenchyma invasion, infiltration of central 
structures including great vessels (Figure 7) or bronchus and 
if the patient’s condition and preoperative lung function tests 
allow it, we conduct an EPP. On the contrary, if macroscopic 
complete resection cannot be achieved (R2), a partial 
pleurectomy is usually performed, without resection of the 
pericardium or diaphragm. 
Conclusions 
Currently, there are no generally accepted criteria for patient 
selection for surgery within a multimodality treatment 
protocol, but patient selection remains the key role for 
surgical success and low morbidity and mortality. Amongst 
clinical, pathological, and molecular prognostic factors 
studied in the past, the combination of several factors seems 
to be the most appropriate tool for decision-making including 
also institutional experience and availability of therapy as well 
as factors such as the patients’ treatment choices. 
At our institution, selection of candidates for surgery 
after induction chemotherapy is based on the following 
factors: Patients of all histological subtypes are eligible for 
surgery within clinical trial protocols, tumor stage T1–
T3, N0–N2 confirmed by mediastinal staging, deemed 
technically resectable by a thoracic surgeon experienced in 
mesothelioma surgery, MMPS ≤2, fit enough for surgery 
in terms of their PS (0–1) and comorbidities and functional 
reserve (including optional EPP).
Obviously, discussion in a multidisciplinary tumor board 
will help to include many aspects in this decision-making 
process and prospective evaluation of these treatment 
allocation protocols will help to select the ideal fitting 
therapy for our patients in the future. The final decision 
for EPP or EPD is taken in most of the cases based on the 
intraoperative findings based on the degree of lung tissue 
infiltration.
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